As filed with the Securities and Exchange Commission on August 12, 2022
Registration No. 333-[•]
 
  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8 
REGISTRATION STATEMENT
Under
The Securities Act of 1933
 
POINT BIOPHARMA GLOBAL INC.
(Exact name of registrant as specified in its charter)
 
Delaware85-0800493
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification Number)
4850 West 78th Street, 
Indianapolis, IN, 46268 
(Address of Principal Executive Offices and Zip)
Point Biopharma Global Inc. 2021 Equity Incentive Plan (the “2021 Plan”)
(Full Title of the Plans)
Bill Demers
4850 West 78th Street,
Indianapolis, IN 
(647) 812-2417 
(Name, address, including zip code, and telephone number, including area code, of agent for service)
 
Copies to:
Susan V. Sidwell, Esq.
Bass Berry & Sims, PLC
150 Third Avenue South
Suite 2800
Nashville, Tennessee 37201
Tel: (615) 742-6200
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐   Accelerated filer ☐
Non-accelerated filer ☒   Smaller reporting company ☒
    Emerging growth company ☒


 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
 



EXPLANATORY NOTE
This Registration Statement on Form S-8 registers 3,604,871 additional shares of common stock, par value $0.0001 per share (“Common Stock”), of POINT Biopharma Global Inc. (the “Registrant”) under the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the “Plan”) as a result of the provision in the Plan providing for an automatic annual increase in the number of shares of Common Stock reserved and available for issuance under the Plan on each January 1, beginning in 2022, by an amount equal to the lesser of: (i) four percent (4%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or (ii) such lesser number of shares of Common Stock as determined by the Registrant’s Board of Directors. Accordingly, on January 1, 2022, the number of shares of Common Stock reserved and available for issuance under the Plan increased by 3,604,871. The Registrant previously registered shares of Common Stock under the Plan on a Registration Statement on Form S-8 (File No. 333-259171) (the “Prior Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) on August 30, 2021.
The information contained in the Registrant’s Prior Registration Statement is hereby incorporated by reference pursuant to General Instruction E, except for Item 8. Exhibits of Part II.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
EXHIBIT INDEX
 


Exhibit
No.		  Description
3.1  
3.2  
5.1*  
23.1*  
Consent of Bass, Berry & Sims PLC (included in Exhibit 5.1)
23.2*  
24.1*  
99.1  
99.2
99.3
99.4
99.5
99.6
107.1*  
 
*Filed herewith.
image_0a.jpg



SIGNATURES
Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, on August 12, 2022.

POINT BIOPHARMA GLOBAL INC.
By:/s/ Bill Demers
Bill Demers
Chief Financial Officer
POWER OF ATTORNEY AND SIGNATURES
Each person whose signature appears below constitutes and appoints each of Joe McCann, and Bill Demers, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dated indicated. 


Name  Title Date
/s/ Joe McCann  Chief Executive Officer (Principal Executive Officer) and Director August 12, 2022
Dr. Joe McCann, Ph.D. 
/s/ Allan C. Silber  Executive Chair and Director August 12, 2022
Allan C. Silber 
/s/ Bill Demers  Chief Financial Officer (Principal Financial and Accounting Officer) August 12, 2022
Bill Demers 
/s/ Neil Fleshner  Chief Medical Officer and Director August 12, 2022
Dr. Neil Fleshner   
/s/ Rajesh K. Malik  Director August 12, 2022
Dr. Rajesh K. Malik, M.D.   
/s/ Jonathan Ross Goodman  Director August 12, 2022
Jonathan Ross Goodman   
/s/ Gerald Hogue  Director August 12, 2022
Gerald Hogue   
/s/ David C. Lubner  Director August 12, 2022
David C. Lubner   
/s/ Yael Margolin  Director August 12, 2022
Dr. Yael Margolin, Ph.D.   

Therapeutics Acquisition (NASDAQ:RACA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Therapeutics Acquisition.
Therapeutics Acquisition (NASDAQ:RACA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Therapeutics Acquisition.